ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Oculis Holding AG

Oculis Holding AG (OCS)

11,21
-0,62
(-5,24%)
Geschlossen 07 Juni 10:00PM
11,12
-0,09
(-0,80%)
Nach Börsenschluss: 1:58AM

Oculis Holding AG (OCS) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
11,12
( -6,00% )
Gebot
8,62
Fragen
12,33
Volumen
871.868
11,17 Tagesbereich 12,045
11,12 52-Wochen-Bereich 34,475
Marktkapitalisierung
Handelsende
11,83
Handelsbeginn
11,67
Letzte Trade
89
@
11.12
Letzter Handelszeitpunkt
Finanzvolumen
US$ 9.960.096
VWAP
11,4239
Durchschnittliches Volumen (3 Mio.)
US$ 425.954
Ausgegebene Aktien
60.388.073
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-10,3
Gewinn pro Aktie (EPS)
-1,72
Erlöse (LTM)
1,12M
Nettogewinn (LTM)
-94,6M

Über Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phas... Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
Zug, Switzerland
Gegründet
2026
Oculis Holding AG is listed in the Healthcare sector of the NASDAQ with ticker OCS. The last closing price for Oculis was US$11,83. Over the last year, Oculis shares have traded in a share price range of US$ 11,12 to US$ 34,475.

Oculis currently has 60.388.073 shares in issue. The market capitalisation of Oculis is US$671,52 million. Oculis has a price to earnings ratio (PE ratio) of -10.30.

Option-Flow Oculis (OCS)

Gesamtfluss

Bullisch

Nettoprämie

35k

Calls / Puts

100,00%

Käuf. / Verkä.

0,00%

OTM / ITM

0,00%

Sweeps

0,00%

OCS Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-18.18-62.0477815729.329.64511.12311025915.13628972CS
4-19.9-64.152159896831.0234.47511.12114916419.52647193CS
12-15.88-58.81481481482734.47511.1259925122.33724609CS
26-8.69-43.866733972719.8134.47511.1242837323.82044889CS
52-8.22-42.502585315419.3434.47511.1223666823.36444899CS
156-0.29-2.5416301489911.4134.4759.0510292421.46107152CS
2600.171.5525114155310.9534.4756.269667221.21196429CS

OCS - Frequently Asked Questions (FAQ)

What is the current Oculis Holding AG share price?
The current share price of Oculis Holding AG is US$ 11,12
How many Oculis Holding AG shares are in issue?
Oculis Holding AG has 60.388.073 shares in issue
What is the market cap of Oculis Holding AG?
The market capitalisation of Oculis Holding AG is USD 671,52M
What is the 1 year trading range for Oculis Holding AG share price?
Oculis Holding AG has traded in the range of US$ 11,12 to US$ 34,475 during the past year
What is the PE ratio of Oculis Holding AG?
The price to earnings ratio of Oculis Holding AG is -10,3
What is the cash to sales ratio of Oculis Holding AG?
The cash to sales ratio of Oculis Holding AG is 954,33
What is the registered address of Oculis Holding AG?
The registered address for Oculis Holding AG is Bahnhofstrasse 20, Zug, Zug, 6300
What is the Oculis Holding AG website address?
The website address for Oculis Holding AG is oculis.com
Which industry sector does Oculis Holding AG operate in?
Oculis Holding AG operates in the Biotechnology & Life Sciences sector

OCS Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen